Risk-Benefit Modelling

Risk-benefit Modelling informs the increasing focus on the safety and efficacy of new therapies from a population perspective, and it jointly evaluates the risks and benefits of competing therapies. This analysis allows the explicit incorporation of patient or societal preferences for the targeted health states, and is a flexible strategy that can employ trial or real-world safety and efficacy/effectiveness data. A risk-benefit Modelling approach is particularly valuable for therapies with potentially contentious or poorly understood safety profiles.

To jointly assess the risks and benefits of treatments for a given condition, we typically employ a Modelling approach.

Model inputs may be synthesised using a variety of methods:

  • Systematic literature review
  • Meta-analysis
  • Administrative database analysis
  • Chart reviews
  • Prospective data collection and registries 

Regulators have taken a special interest in risk benefit studies because of their contribution towards the lifecycle management approach to drug licensure that many countries are moving towards. Our epidemiology team has a wealth of experience in conducting risk-benefit Modelling and we are able to use this expertise to provide a well informed and thorough service either as a standalone product or in conjunction with our other services.